Het individualiseren van de dosering van docetaxel door middel van een Microdose.

This study will be a single center cross-sectional prospective pharmacokinetic study. Patients with breast-, prostate, non-small cell lung carcinoma (NSCLC), who are already eligible for therapeutic treatment with docetaxel as a part of routine care will receive a bolus microdose (1000ìg) of intravenous docetaxel 1 to 7 days prior to the therapeutic docetaxel administration. Blood samples will be taken. The aim is to establish the relationship between a microdoce and therapeutic dose docetaxel pharmacokinetic and to develop a limiting sampling model for prediction of therapeutic dose docetaxel pharmacokinetics from a microdoce docetaxel.

Docetaxel has a narrow therapeutic index and shows a wide interpatient variability in clearance and toxicity. There is a need for a tool to predict efficacy of docetaxel in individual patients.
We hypothesize that the pharmacokinetics of a microdose and therapeutic dose of docetaxel can be reliably interpolated.

- Pharmacokinetics after 0.25, 1, 2, 4, 6 and 8 hours after end of infusion of the microdose and the therapeutic dose of doxetaxel.

- Microdose Docetaxel (1000 ìg)

Patients who are already eligible for therapeutic treatment with docetaxel as a part of routine care will receive a bolus microdose (1000ìg) of intravenous docetaxel 1 to 7 days prior to the therapeutic docetaxel administration.